Related Experiment Video
Updated: Aug 30, 2026

Intratracheal Instillation of Stem Cells in Term Neonatal Rats
Published on: May 4, 2020
[Exogenous surfactant therapy in pediatrics]
Norberto A Freddi1, José Oliva Proença Filho, Humberto H Fiori
1Hospital Santa Catarina, São Paulo, SP, Brazil. nafreddi@uol.com.br
Insights
Exogenous surfactant therapy shows success in neonatal Respiratory Distress Syndrome (RDS), but optimal timing and use in other pediatric acute respiratory failure conditions require further investigation and improved surfactant formulations.
Area of Science:
- Pediatric Pulmonology
- Critical Care Medicine
- Biochemistry
Context:
- Acute respiratory failure in children presents significant clinical challenges.
- Exogenous surfactant replacement therapy is established for neonatal Respiratory Distress Syndrome (RDS).
- Limited and conflicting data exist regarding surfactant use in other pediatric lung diseases.
Purpose:
- To review current knowledge on exogenous surfactant use for pediatric acute respiratory failure.
- To identify knowledge gaps and areas for future research in pediatric surfactant therapy.
Summary:
- While successful in neonatal RDS, optimal timing of exogenous surfactant administration remains debated.
- Surfactant efficacy in other severe pediatric lung diseases requiring ventilatory support is controversial.
- Research is exploring surfactant inactivation mechanisms and developing novel, inhibition-resistant formulations.
Impact:
- Highlights the need for further research into optimizing surfactant therapy for various pediatric respiratory conditions.
- Suggests potential for improved treatment strategies through enhanced surfactant properties and targeted administration.
- Emphasizes the importance of investigating surfactant resistance to airway inhibitors for broader clinical application.
Objective:
To review current knowledge about the use of exogenous surfactants in the treatment of different lung diseases causing acute respiratory failure in children.
Source Of Data:
This review is based on the author's experience and on recent data retrieved from ONIA, Mdconsult, Medline and the Cochrane Database Library.
Summary Of The Findings:
In spite of the success of the use of exogenous surfactants in Respiratory Distress Syndrome (RDS) of the newborn, some questions remain unanswered, such as the optimal administration timing - either very early (prophylactic), based on gestational age or on quick tests of lung maturity, or later, when the clinical picture becomes unequivocal. In other severe diseases requiring ventilatory support, the use of surfactants is still controversial, and data in the literature are limited and conflicting. However, successful use in several other diseases has been reported. Recent studies have focused on surfactant inactivation by substances that can be found in the airways. New surfactants with the addition of substances to control inhibition, such as polyethyleneglycol, are being tested for diseases in which inactivation seems to be a significant factor.
Conclusions:
Therapy with exogenous surfactants, even as a treatment for RDS, has not been thoroughly investigated. Further studies should be conducted to improve surfactants - mainly their resistance to inhibition - and the treatment of diseases other than RDS.
More Related Videos
08:58Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs
Published on: October 31, 2025
06:22Surfactant Depletion Combined with Injurious Ventilation Results in a Reproducible Model of the Acute Respiratory Distress Syndrome (ARDS)
Published on: April 7, 2021
Related Concept Videos
Breathing
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Pulmonary Cycle: Exhalation